Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

44 results about "Fatty acid level" patented technology

Sophorolactone production

The present invention relates to a process for selectively producing sophorolactone without use of organic solvent, comprising the steps of: -pre-cultivating cells of a Candida species capable of producing sophorolactone, in absence of an oily substrate until a stationary growth phase is obtained, -cultivating said pre-cultivated cells in an aqueous medium in the presence of at least one fermentable sugar and substrate; the reaction mixture of sugar, substrate and pre-cultivated cells being present in an amount and conditions such that the cells metabolize the sugar and substrate thereby forming sophorolactone and fatty acid, -continuously feeding said substrate to said cells thereby suppressing the formation of fatty acid and keeping fatty acid levels in the reaction mixture below 10 g/l, resulting in the crystallization of at least part of the sophorolactone present in the reaction mixture, -warming the reaction mixture to a temperature between 60° C. and 90° C., thereby melting the sophorolactone crystals, -allowing the molten sophorolactone to settle and to provide a crude sophorolactone composition, and -removing the crude sophorolactone composition from the remainder of the reaction mixture without use of an organic solvent.
Owner:ECOVER CO ORDINATION CENT

Fatty acid markers for the diagnosis, prognosis and management of cardiovascular disease

Methods of detecting myocardial infarction are disclosed based on elevated levels of one or more free fatty acids. The methods may comprise detection of elevated levels of total free fatty acids in a sample relative to average total free fatty acid levels in a control subject without myocardial infarction. Also disclosed are methods to detect myocardial infarction comprising detection of elevated levels of individual free fatty acids in a sample relative to those levels in a control subject and methods comprising determining whether the molar ratio of total free fatty acids to HSA is indicative of myocardial infarction.
Owner:BHAGAVAN NADHIPURAM V +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products